Clinical Trial

A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET

Study acronym: REFINE
Recruiting
View on ClinicalTrials.gov →
Summary
The REFINE study is evaluating whether a fluciclovine (18F) PET/CT scan can detect recurrent prostate cancer in patients whose previous PSMA PET/CT was negative or inconclusive.
Trial Details
NCT Number NCT06859203
Lead Sponsor Technical University of Munich
Conditions Biochemical Recurrence of Malignant Neoplasm of Prostate
Enrollment 94 participants
Start Date 2025-03
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-05